Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIPP-PrEP
NCT07672717Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jul 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by Johns Hopkins University. Primary endpoints: Plasma Cabotegravir concentration at Week 12, Plasma Cabotegravir area under the concentration curve and 4 more. Started Jul 2026; status: recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07672717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672717.